Overview

Biologic Therapy in Pediatric JIA Uveitis

Status:
Active, not recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
Juvenile Idiopathic Arthritis (JIA) remains the most common systemic disorder associated with pediatric uveitis. Studies estimate that 28-67% of patients with JIA-associated uveitis develop ocular complications, with 12% developing poor visual outcome. The only means of improving long term effects of uveitis, is early and aggressive anti-inflammatory treatment, including biologics.
Phase:
Phase 4
Details
Lead Sponsor:
Kasr El Aini Hospital
Treatments:
Adalimumab